Quarterly ResultAug 13, 2026, 05:18 PM
Celcuity Q2 Net Loss $78.9M; Stockholders' Deficit $12.8M
AI Summary
Celcuity Inc. reported a net loss of $78.9 million for the second quarter of 2026, widening from $45.3 million in the prior year, and an accumulated deficit of $580.6 million, leading to a stockholders' deficit of $12.8 million. Despite these financial results, the company highlighted its FDA-approved drug REVTORPYK (gedatolisib) and ongoing Phase 3 and Phase 1b/2 clinical trials. Celcuity also increased its convertible notes to $753.2 million and accrued a $50 million license milestone, while maintaining $754.0 million in cash, cash equivalents, and short-term investments, sufficient to fund operations for at least one year.
Key Highlights
- Net loss for Q2 2026 was $78.9 million, compared to $45.3 million in Q2 2025.
- Net loss for H1 2026 was $131.7 million, compared to $82.3 million in H1 2025.
- Stockholders' equity shifted to a deficit of $12.8 million as of June 30, 2026.
- Convertible notes increased to $753.2 million from $195.3 million at year-end 2025.
- Accrued license milestone reached $50.0 million as of June 30, 2026.
- Cash, cash equivalents, and short-term investments totaled $754.0 million.
- Selling, general and administrative expenses rose to $52.5 million for H1 2026.
- The company has FDA approval for REVTORPYK (gedatolisib) and ongoing clinical trials.
Price Impact
More from CELC